Sovaldi (sofosbuvir) / Gilead 
Welcome,         Profile    Billing    Logout  
 18 Diseases   22 Trials   22 Trials   2501 News 


«12345678910111213...2122»
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal:  Monitoring of iron, lipid and liver profiles in Egyptian hepatitis C virus patients on sofosbuvir therapy. (Pubmed Central) -  Mar 16, 2022   
    The result showed that, the increased serum iron (205.59±8.27 μg/dl), cholesterol (237.96 ± 10.92 mg/dl), triglycerides (246.58 ± 8.23 mg/dl), LDL (172.82 ± 8.47 mg/dl), VLDL (50.91 ± 1.65 mg/dl), AST (164.58 ± 8.45 U/L), ALP (142.61 ± 7.41 U/L) in hepatitis C virus patients was significantly decreased (P < 0.05) upon treatment with sofosbuvir and the decreased serum ferritin (18.55±1.39 ng/dl), transferrin (128.41 ± 6.43 mg/dl), total iron binding capacity (204.41 ± 8.82 mg/dl), total protein (5.81 ± 0.24 g/dl), albumin (2.83 ± 0.09 g/dl) and HDL (14.22 ± 1.17 mg/dl) in hepatitis C virus patients was significantly increased (P < 0.05) upon treatment with sofosbuvir. According to our finding we concluded that, treatment with sofosbuvir 12 week ameliorate disruption of iron, lipid and liver parameters caused by infection with Hepatitis C virus.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal:  Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy. (Pubmed Central) -  Mar 11, 2022   
    We investigated HBsAg and HBV-DNA kinetics in fifteen untreated HBeAg Negative Infection (ENI) (4F-11M, 62.1y) and eight Nucleos(t)ide Analogs (NAs) treated Chronic Hepatitis B (CHB) (3F-6M, 54.8y) with HCV co-infection, receiving DAAs-regimens including Sofosbuvir (13) or not (10)...In conclusion, HBV reactivations during DAAs in HCV co-infected ENI caused moderate increases of HBV-DNA without ALT elevations. The concomitant HBsAg decline, although significant, did not modify individual pre-treatment profiles.
  • ||||||||||  pibrentasvir (ABT-530) / AbbVie, Sovaldi (sofosbuvir) / Gilead
    Preclinical, Journal:  Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture. (Pubmed Central) -  Mar 8, 2022   
    In the presence of Pibrentasvir, RNAs terminated with the active forms of the prodrugs Sofosbuvir, Remdesivir, Favipiravir, Molnupiravir and AT-527 were largely protected from excision by the exonuclease, while in the absence of Pibrentasvir, there was rapid excision...Viral cell culture studies also demonstrate significant synergy using this combination strategy. This study supports the use of combination drugs that inhibit both the SARS-CoV-2 polymerase and exonuclease for effective COVID-19 treatment.
  • ||||||||||  seraprevir (GP-205) / GinkgoPharma, Sovaldi (sofosbuvir) / Gilead
    Clinical, P3 data, Journal:  Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: a single-arm, open-label, phase 3 trial. (Pubmed Central) -  Mar 1, 2022   
    Sofosbuvir was found to bind nsp12 with comparable binding energies to that of Remdesivir, which has been reported for its potential against COVID-19 RdRp and is currently approved by the FDA. The all-oral, ribavirin-free regimen of seraprevir and sofosbuvir is an effective and well-tolerated treatment option for Chinese patients mono-infected with HCV, including those with a history of interferon treatment.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal:  Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN. (Pubmed Central) -  Mar 1, 2022   
    Molecular dynamics simulations further show remarkable flexibility of multidomain nsp14 and suggest that nsp10 stabilizes ExoN for substrate RNA binding to support its exonuclease activity. Our high-resolution structure of the SARS-CoV-2 ExoN-nsp10 complex serves as a platform for future development of anticoronaviral drugs or strategies to attenuate the viral virulence.
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  REVOLUTIOn: Antiviral Agents Against COVID-19 Infection (clinicaltrials.gov) -  Feb 28, 2022   
    P2/3,  N=256, Active, not recruiting, 
    Our high-resolution structure of the SARS-CoV-2 ExoN-nsp10 complex serves as a platform for future development of anticoronaviral drugs or strategies to attenuate the viral virulence. Recruiting --> Active, not recruiting | N=1005 --> 256 | Trial completion date: Feb 2022 --> Dec 2022 | Trial primary completion date: Nov 2021 --> Aug 2021
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Review, Journal:  INSIGHTS INTO THE BIOLOGICAL IMPACT OF COVID-19 AND ITS VACCINES ON HUMAN HEALTH. (Pubmed Central) -  Feb 22, 2022   
    Molnupiravir, an orally active RdRp inhibitor and noval broad spectrum antiviral agent, is an isopropyl pro-drug of EIDD-1931 for emergency use...Top seeds for antiviral treatments with high potential to combat the SARS-CoV-2 strain include guanosine derivatives (IDX-184), setrobuvir, and YAK. The goal of this review is to compile scattered information on available COVID-19 vaccines and other treatments for protecting the human body from their harmful effects and to provide options for making better choices in a timely manner.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Review, Journal:  Transfusion-transmitted hepatitis E: What we know so far? (Pubmed Central) -  Feb 8, 2022   
    Immunosuppressed patients who develop persistent hepatitis E infection should have their immunosuppressant regimen reduced; ribavirin may be considered as treatment...Sofosbuvir, a nucleotide analog, showed modest antiviral activity in some clinical studies but sustained viral response was not achieved...Various pathogen reduction methods have also been proposed to reduce the risk of TT-HEV. Future studies are needed to define the incidence of transmission through transfusion, their clinical features, outcomes and prognosis.
  • ||||||||||  Asclevir (ravidasvir) / Presidio Pharma, Ascletis, Pharco Pharmaceuticals, Sovaldi (sofosbuvir) / Gilead
    EFFICACY & SAFETY OF RAVIDASVIR + SOFOSBUVIR IN HEPATITIS C: STORM-C-1 FINAL RESULTS ([VIRTUAL]) -  Feb 7, 2022 - Abstract #CROI2022CROI_1125;    
    There were no significant drug-drug interactions requiring switching of anti-retroviral therapies. Ravidasvir with sofosbuvir is well tolerated with excellent safety and efficacy in HCV infection, including difficult to treat populations, making it suitable for implementation in public health settings.
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma, Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  Sofosbuvir, glecaprevir, pibrentasvir, and ribavirin as a rescue therapy in difficult-to-treat hepatitis C patients. (Pubmed Central) -  Jan 13, 2022   
    Pangenotypic direct-acting antiviral (DAA) drugs have a hepatitis C (HCV) cure rate of >95% in almost all treated patients. When DAA treatment fails, retreatment must be guided by virus resistance profiles, and phase III trials have reported sustained virological responses (SVR) of 96-98% after a 12-week course of sofosbuvir (SOF), velpatasvir (VEL), and voxilaprevir (VOX).
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal:  Advancement of prodrug approaches for nucleotide antiviral agents. (Pubmed Central) -  Jan 13, 2022   
    This review will focus on the summary of design approach and metabolic activation path of different nucleotide prodrug strategies. The potential application of nucleotide prodrugs for treatment of COVID-19 was also described due to the pandemic of SARS-CoV-2.
  • ||||||||||  Elpida (elsulfavirine) / Viriom
    Trial completion:  Study to Evaluate the Safety and PK of Elpida (clinicaltrials.gov) -  Jan 11, 2022   
    P1,  N=36, Completed, 
    Enrolling by invitation --> Active, not recruiting Recruiting --> Completed
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal:  Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections. (Pubmed Central) -  Jan 7, 2022   
    This work critically reviews the recent advances in chromatographic methods for the analysis of sofosbuvir and/or its metabolites in pure samples, pharmaceutical dosage forms, and in presence of other co-administrated drugs to highlight the current status and future perspectives to enhance its determination in different matrixes. Altogether, our results indicated that IFNα can be combined with drugs that affect viral RNA transcription, protein synthesis, and processing to make synergistic combinations that can be attractive targets for further pre-clinical and clinical development against emerging and re-emerging viral infections.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  Small-molecule antiviral agents in ongoing clinical trials for COVID-19. (Pubmed Central) -  Jan 6, 2022   
    These include viral polymerase and protease inhibitors remdesivir, galidesivir, favipiravir, ribavirin, sofosbuvir, tenofovir/emtricitabine, baloxavir marboxil, EIDD-2801, lopinavir/ritonavir; virus-/host-directed viral entry and fusion inhibitors arbidol chloroquine/hydroxychloroquine, chlorpromazine, camostat mesylate, nafamostat mesylate, bromhexine and agents with diverse/unclear mechanism of actions as oseltamivir, triazavirin, ivermectin, nitazoxanide, niclosamide and BLD-2660. The published preclinical and clinical data to date on these drugs as well as the mechanisms of action are reviewed.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors. (Pubmed Central) -  Jan 1, 2022   
    Six US transplant programs prospectively treated D+/R- primary LT and KT recipients with sofosbuvir-velpastasvir for 12 weeks starting once viremia was confirmed following transplant and the patients were judged to be clinically stable, including estimated glomerular filtration rate >30 mL/min...We conclude that despite differing kinetics of early HCV infection in liver versus non-liver recipients, a preemptive antiviral strategy is effective. Vigilance for adverse immunologic events is warranted.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Clinical, Review, Journal:  Public funding for transformative drugs: the case of sofosbuvir. (Pubmed Central) -  Dec 21, 2021   
    Of 6043 unique awards, we identified 29 directly (N = US$7.7 million) and 110 indirectly (N = US$53.2 million) related awards dispersed to important academic institutions and companies engaged in the development of the drug. These findings indicate that public funding had a key role in developing sofosbuvir, with an estimated US$60.9 million provided in NIH funding.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  Access to medicines and South-South cooperation: a case study on joint drug price negotiations in South America (Pubmed Central) -  Dec 16, 2021   
    In the case of darunavir, there was a reduction in the global price, including the price in the Global Fund to Fight AIDS, Tuberculosis, and Malaria. In conclusion, price negotiation was successful in the above-mentioned cases, and participation by the PAHO Strategic Fund in the drug purchases streamlined their procurement and their availability in the countries.